NCT06346691CompletedPhase 4
Effects of Oral Doxofylline and Procaterol on Chronic Obstructive Pulmonary Disease
Bronchodilator Effect of Oral Doxofylline and Procaterol in Chronic Obstructive Pulmonary Disease : a Randomized Crossover Study
Source: ClinicalTrials.gov · Last updated 20 Jan 2025
Brief summary (registry, in English)
The goal of this clinical trial is to determine if doxofylline and procaterol are effective in treating patients with stable chronic obstructive pulmonary disease (COPD). It will also assess the safety of both drugs. The main questions it aims to answer are: * Does doxofylline demonstrate a comparable bronchodilator effect to procaterol in COPD participants? * What medical problems do participants experience when taking doxofylline and procaterol?"
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 28 Mar 2024
- Start date
- 1 Mar 2024
- Primary completion date
- 31 Oct 2024
- Lead sponsor
- Thammasat University
- Diseases
- COPD
- NCT number
- NCT06346691
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 20
- From 1 Mar 2024 to the primary completion date, 31 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Oral or intravenous corticosteroid treatment within 6 weeks
- Oral bronchodilators e.g. doxofylline, theophylline, procaterol, or salbutamol within 1 week before randomization
Other illness
- History of COPD exacerbation within 3 months
Other
- Asthma
- Tracheostomy, invasive or noninvasive mechanical ventilation
- Inability to perform spirometry or 6-minute walk test
- Pregnant or breastfeeding women
Who the study is looking for
- COPD diagnosis confirmed by spirometry (post-bronchodilator FEV1/FVC \< 70%)
- Aged 40 years or older
- Smoking 10 pack-years or more
- Postbronchodilator FEV1 \< 80%
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Narongkorn Saiphoklang Coordinator of this site? Confirm its status | Klongluang | Thailand | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.